Current Status of Potential Therapies for IgE-Mediated Food Allergy

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose of Review: The goal of this review is to provide the reader with an updated summary of published trial data regarding the use of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) for treatment of IgE-mediated food allergies. Recent Findings: Data from phase 2 trials for treatment of peanut allergy with OIT and EPIT reveal an increase in the threshold of reactivity for peanut-allergic children. Compared to EPIT, OIT promotes a greater increase in the threshold of reactivity; however, adverse events are more common with OIT. Summary: OIT, EPIT, and SLIT appear to modulate the immune response for some food-allergic individuals. Data regarding utility for treatment of food allergies regardless of modality is limited to few foods, as is investigation into treatment of food-allergic infants, young children, and adults. Future trials are likely to focus on young children, food allergies other than peanut, and treatment of multifood-allergic individuals.

Original languageEnglish (US)
Article number18
JournalCurrent Allergy and Asthma Reports
Volume18
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Food Hypersensitivity
Immunotherapy
Immunoglobulin E
Sublingual Immunotherapy
Therapeutics
Peanut Hypersensitivity
Infant Food
Food
Young Adult

Keywords

  • Epicutaneous immunotherapy
  • EPIT
  • Food allergy
  • Milk allergy
  • OIT
  • Oral immunotherapy
  • Peanut allergy
  • SLIT
  • Sublingual immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Current Status of Potential Therapies for IgE-Mediated Food Allergy. / Parrish, Christopher P.; Har, Daniel; Andrew Bird, J.

In: Current Allergy and Asthma Reports, Vol. 18, No. 3, 18, 01.03.2018.

Research output: Contribution to journalReview article

@article{0cb4b9ae8b1749d48e38a7fae533605f,
title = "Current Status of Potential Therapies for IgE-Mediated Food Allergy",
abstract = "Purpose of Review: The goal of this review is to provide the reader with an updated summary of published trial data regarding the use of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) for treatment of IgE-mediated food allergies. Recent Findings: Data from phase 2 trials for treatment of peanut allergy with OIT and EPIT reveal an increase in the threshold of reactivity for peanut-allergic children. Compared to EPIT, OIT promotes a greater increase in the threshold of reactivity; however, adverse events are more common with OIT. Summary: OIT, EPIT, and SLIT appear to modulate the immune response for some food-allergic individuals. Data regarding utility for treatment of food allergies regardless of modality is limited to few foods, as is investigation into treatment of food-allergic infants, young children, and adults. Future trials are likely to focus on young children, food allergies other than peanut, and treatment of multifood-allergic individuals.",
keywords = "Epicutaneous immunotherapy, EPIT, Food allergy, Milk allergy, OIT, Oral immunotherapy, Peanut allergy, SLIT, Sublingual immunotherapy",
author = "Parrish, {Christopher P.} and Daniel Har and {Andrew Bird}, J.",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s11882-018-0772-z",
language = "English (US)",
volume = "18",
journal = "Current Allergy and Asthma Reports",
issn = "1529-7322",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Current Status of Potential Therapies for IgE-Mediated Food Allergy

AU - Parrish, Christopher P.

AU - Har, Daniel

AU - Andrew Bird, J.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose of Review: The goal of this review is to provide the reader with an updated summary of published trial data regarding the use of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) for treatment of IgE-mediated food allergies. Recent Findings: Data from phase 2 trials for treatment of peanut allergy with OIT and EPIT reveal an increase in the threshold of reactivity for peanut-allergic children. Compared to EPIT, OIT promotes a greater increase in the threshold of reactivity; however, adverse events are more common with OIT. Summary: OIT, EPIT, and SLIT appear to modulate the immune response for some food-allergic individuals. Data regarding utility for treatment of food allergies regardless of modality is limited to few foods, as is investigation into treatment of food-allergic infants, young children, and adults. Future trials are likely to focus on young children, food allergies other than peanut, and treatment of multifood-allergic individuals.

AB - Purpose of Review: The goal of this review is to provide the reader with an updated summary of published trial data regarding the use of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) for treatment of IgE-mediated food allergies. Recent Findings: Data from phase 2 trials for treatment of peanut allergy with OIT and EPIT reveal an increase in the threshold of reactivity for peanut-allergic children. Compared to EPIT, OIT promotes a greater increase in the threshold of reactivity; however, adverse events are more common with OIT. Summary: OIT, EPIT, and SLIT appear to modulate the immune response for some food-allergic individuals. Data regarding utility for treatment of food allergies regardless of modality is limited to few foods, as is investigation into treatment of food-allergic infants, young children, and adults. Future trials are likely to focus on young children, food allergies other than peanut, and treatment of multifood-allergic individuals.

KW - Epicutaneous immunotherapy

KW - EPIT

KW - Food allergy

KW - Milk allergy

KW - OIT

KW - Oral immunotherapy

KW - Peanut allergy

KW - SLIT

KW - Sublingual immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85042364612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042364612&partnerID=8YFLogxK

U2 - 10.1007/s11882-018-0772-z

DO - 10.1007/s11882-018-0772-z

M3 - Review article

C2 - 29470658

AN - SCOPUS:85042364612

VL - 18

JO - Current Allergy and Asthma Reports

JF - Current Allergy and Asthma Reports

SN - 1529-7322

IS - 3

M1 - 18

ER -